# Amphastar Pharmaceuticals Inc. (AMPH) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $23.18, market value $986 million.

## Valuation
- **P/E (trailing): 13.7×** (5-yr avg 16.8×, 3-yr avg 16.4×). Amphastar Pharmaceuticals Inc. trades at 13.7× trailing earnings, close to its own five-year average of 16.8×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 7.3×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 1.4×**. Each dollar of revenue is priced at 1.4×.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 15.5%** (5-yr avg 6.7%). Free cash flow equals 15.5% of the market value, above its five-year average of 6.7%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 7.3%**. The inverse of the P/E: 7.3% of the price is earned each year.

## Profitability
- **Gross margin: 47.7%**. Amphastar Pharmaceuticals Inc. keeps 47.7% of revenue after the direct cost of what it sells.
- **Operating margin: 15.7%**. 15.7% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 13.6%**. 13.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.4%**. 12.4% on shareholders' equity is solid.
- **Return on invested capital: 7.3%**. Return on all capital, debt included, is 7.3%.
- **Return on assets: 4.8%**. Each dollar of assets produces 4.8% of profit.

## Growth
- **Revenue growth (1 yr): -1.7%** (3-yr 13.0%/yr, 5-yr 15.5%/yr). Revenue fell 1.7% over the last year, against 15.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -33.7%** (3-yr 5.3%/yr, 5-yr 132.3%/yr). Earnings per share fell 33.7%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 23.0%/yr**. Free cash flow has compounded at 23.0% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.79**. Debt is 0.79 times equity, moderate leverage.
- **Altman Z-score: 2.11**. A Z-score of 2.11 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Amphastar Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (6 analysts). 6 analysts cover Amphastar Pharmaceuticals Inc.; the consensus is hold, with an average price target of $22.50 (-3% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -20.6%** (YTD -13.4%, 3-mo 17.4%). The shares are down 20.6% over twelve months including dividends.
- **From 52-week high: -21.5%** (39.2% above the low). Trading 21% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 66**. An RSI of 66 is neutral.
- **Beta (1 yr): 0.67** (volatility 51%). Beta of 0.67 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AMPH · Page: https://foliofundamentals.com/stocks/amph

Not investment advice.